stockmarketproxy
/
JAZZNasdaq SEC EDGAR

Jazz Pharmaceuticals plc

Pharmaceutical Preparations·DUBLIN·FY end 12/31·CIK 1232524
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$4.3B$4.1B$3.8B$3.7B$3.1B
Gross Profit——————
Operating Income-$430.2M$716.6M$578.6M-$65.5M$170.3M
Net Income-$356.1M$560.1M$414.8M-$224.1M-$329.7M
Operating CF$1.4B$1.4B$1.1B$1.3B$778.5M
Capex$58.8M$38.1M$24.0M$29.0M$27.6M
Free Cash Flow$1.3B$1.4B$1.1B$1.2B$750.9M
Buybacks$125.0M$311.4M$269.8M$54.0K$0
Dividends——————
Gross Margin——————
Operating Margin-10.1%17.6%15.1%-1.8%5.5%
Net Margin-8.3%13.8%10.8%-6.1%-10.7%
FCF Margin30.4%33.4%27.9%34.0%24.3%
R&D / Revenue——————
Effective Tax——————
Debt / Equity2.242.982.903.703.04
Buybacks / FCF9.6%22.9%25.3%0.0%0.0%

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
JAZZ
55:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
JAZZ
$16M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
JAZZ
-8.3%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%